The expansion plans cover activated mPEG manufacturing and development of APIs for use in pre-clinical through to commercial development
The Custom Pharmaceutical Services (CPS) business of Dr. Reddy’s Laboratories is to expand in the areas of activated mPEG manufacturing and in the development and manufacture of New Chemical Entities (NCEs) for use in pre-clinical through to commercial development at its manufacturing facility in Mirfield, UK.
The expansion puts Dr Reddy's at the forefront of activated mPEG manufacturing and will enable manufacture of its PEGtechTM range at commercial metric tonne scale quantities and beyond in a fully cGMP environment.
Equipped with state-of-the-art DCS computer control systems, the plant operates with a very high level of control and has been designed with the latest manufacturing compliance standards in mind.
Commenting on the development, Dr Ananthanarayanan, president pf Pharmaceutical Services and Active Ingredients business, Dr Reddy’s said: ‘This expansion builds on our commitment to expand operations in UK and provide a superior network of cGMP manufacturing to support our global customer base. PEGylation is one area where we felt the need for expanding our capabilities. We have invested in multiple technology areas and the expansion will add significant value in the areas of mPEGs and cGMP API manufacturing’.
The company has eight API manufacturing facilities (Six FDA-approved plants in India, One FDA-approved plant in Mexico and One FDA-approved plant in Mirfield, UK) worldwide which helps the CPS business to provide its customers with multiple site options.